Compass Pathways outlines potential 30- to 60-day FDA review target as it plans to complete COMP360 NDA in next 2 weeks
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Health & Medicine
Bioengineered retracts 119 more papers as investigation continues
Bioengineered retracted 119 papers in October amid investigations into suspected paper mill activity and other integrity-related concerns at the Taylor & Francis journal.
France's dermatology crisis: Patients desperate for appointments
Around 200,000 cases of skin cancer are diagnosed in France every year. Yet as more and more patients seek medical advice, getting an appointment with a dermatologist is becoming increasingly…
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
What Will the Midterms Mean for Healthcare?
(MedPage Today) -- In this 43-minute webinar, MedPage Today Editor-in-Chief Jeremy Faust, MD, speaks with Larry Levitt, executive vice president for health policy at KFF, about the issues shaping…
I was told I was too young to have cancer
Beth Jenkins' cancer was initially missed after told she was "too young" to have the disease.